Most recently, overexpressed SMYD3 enhanced MMP2 and CDK2 expression in hepatocellular carcinoma and upregulated Bcl-2, Bcl-xl, MMP-2, and MMP-9 in NSCLC to facilitate tumorigenicity and cancer progression [195,196]. Here, SMYD3 is linked to hepatocellular carcinoma.